hotspot -WSS

hotspot

author：explore 2025-08-31 13:15:28 - browse：391

A psilocybin mushroom lays inside a clear capsule — Adobe

A single dose of psilocybin may have enduring benefits for people with major depressive disorder, according to a randomized clinical trial published Thursday in the Journal of the American Medical Association.

Several prior studies have suggested that psilocybin, the psychedelic compound produced by certain types of mushrooms, could be a promising way to treat major depression in people for whom antidepressants or counseling aren’t effective. But those studies mostly focused on short-term results, while the new JAMA study looked at psilocybin’s efficacy up to six weeks after the administration of a single dose of psilocybin.

“It’s exciting to see another study that’s coming out that is adding to the evidence base suggesting potential efficacy of psilocybin for depression, amongst other conditions,” said Greg Fonzo, an assistant professor and co-director for the Center for Psychedelic Research and Therapy at the University of Texas at Austin’s Dell Medical School, who was not involved in the study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： TikTok cracks down on users posting about weight loss drugs

focus

WSS

States increasingly look to regulate hospital facility fees

Stanford updates investigation of president’s past research

Ebola public health emergency is over, WHO declares

New warning issued for rebooking air travel after delays, cancellations

David Ricks of Eli Lilly: best biopharma CEO of 2023

Why health records don't always know when patients are dead

entertainment

hotspot

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Stanford president to resign after investigation of research

The cancer drug shortage isn’t new — and neither are the solutions

TikTok cracks down on users posting about weight loss drugs

State Dept. review finds Biden bears some blame for Afghanistan failures

CRISPR gene editing developments we’re watching in 2024

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Why health care costs have stayed mostly flat since 2010

Trump demands the U.S. pay no more for drugs than other countries … again

Researchers separate signal from noise in heart wearable data

entertainment

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Couple fighting to bring baby home from Mexico are finally reunited

Why some people catch Covid but never get sick

Grail spinoff by Illumina should end disastrous merger attempt

Stanford updates investigation of president’s past research

Medical experts are missing from AI regulatory conversations

focus

focus

leisure time

explore